Aastrom Biosciences Appoints Steven Wolff, M.D. As Vice President Medical Research

- Aastrom Strengthens Senior Management Team -



Apr 10, 2001, 01:00 ET from Aastrom Biosciences, Inc.

    ANN ARBOR, Mich., April 10 /PRNewswire Interactive News Release/ --
 Aastrom Biosciences, Inc. (Nasdaq:   ASTM) announced today that Steven N. Wolff,
 M.D. has joined the Company as Vice President Medical Research.  In this newly
 created position, Dr. Wolff will be responsible for clinical and biological
 research activities at Aastrom, in addition to furthering the development of
 research collaborations in the rapidly emerging field of cell therapeutics.
     "Aastrom has progressed to the stage where a majority of our operations
 are now focused in the clinic, with both trials and commercial applications.
 The addition of Dr. Wolff to Aastrom's senior management team is welcomed, and
 is expected to greatly improve our clinical expertise and help move our
 products into medical practice," stated R. Douglas Armstrong, Ph.D., President
 and Chief Executive Officer of Aastrom.  "Dr. Wolff is a highly credentialed
 medical leader with extensive leadership experience in stem cell
 transplantation, hematology and oncology, which is ideally matched with
 Aastrom's lead stem cell and cancer vaccine product programs."
     Prior to joining Aastrom, Dr. Wolff held various distinguished positions
 at the Vanderbilt University School of Medicine, most recently as Professor of
 Medicine in the Division of Hematology/Oncology, and as Director of the Bone
 Marrow Transplant Program.  In addition, Dr. Wolff has served on the National
 Marrow Donor Program Council since 1995, as the Council's President in 1997,
 and as the Chairman of the Finance Committee.  Currently, Dr. Wolff
 participates as a Board Member for the Lance Armstrong Foundation, having
 served as its Board President in 1998.  Dr. Wolff holds an M.D. from the
 University of Illinois, with postgraduate training at Vanderbilt University
 School of Medicine and Washington University School of Medicine, and holds an
 undergraduate degree from Queens College.
     Aastrom is pioneering the development of proprietary cell therapeutics and
 cell products based on the Company's dual-technology platforms: patented
 "single-pass perfusion" providing cells with enhanced biological function, and
 patented GMP-compliant system automation facilitating the delivery of cells
 for therapeutic use into medical practice.  These technologies are integrated
 into the AastromReplicell(TM) System that is designed to uniquely standardize
 and automate the processes involved in producing high quality therapeutic
 cells.  Aastrom is developing the DC-I dendritic cell product for use in the
 rapidly emerging cancer vaccine market, and the OC-I bone progenitor cell
 product for the treatment of degenerative bone diseases such as osteoporosis.
 The AastromReplicell(TM) System, the SC-I bone marrow stem cell product and
 the CB-I cord blood stem cell product have received CE Mark approval necessary
 for European marketing and are in late-stage U.S. clinical trials.  These
 products are not available for sale at this time in the U.S., except for
 research or investigational use.
     Please visit our website at http://www.aastrom.com
 
     This document contains forward-looking statements, including without
 limitation, statements concerning intended areas of research, product and
 clinical development objectives, clinical trial results, commercialization
 plans and progress, potential product applications, and potential advantages
 of the AastromReplicell(TM) System, which involve certain risks and
 uncertainties.  The forward-looking statements are also identified through use
 of the words "designed," "expected," and other words of similar meaning.
 Actual results may differ significantly from the expectations contained in the
 forward-looking statements.  Among the factors that may result in differences
 are the results obtained from clinical trial and development activities,
 regulatory approval requirements, the availability of resources, competitive
 developments, the availability of resources and the allocation of resources
 among different potential uses.  These and other significant factors are
 discussed in greater detail in Aastrom's Annual Report on Form-10K and other
 filings with the Securities and Exchange Commission.
 
     CONTACTS:  Todd E. Simpson              Noonan/Russo Communications, Inc.
                VP Finance                   Phone:  212-696-4455
                & Administration, CFO        Hala Bashir, ext. 356 (media)
                Aastrom Biosciences, Inc.    David Walsey, ext. 230 (investors)
                Phone:  734-930-5777
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X75876227
 
 

SOURCE Aastrom Biosciences, Inc.
    ANN ARBOR, Mich., April 10 /PRNewswire Interactive News Release/ --
 Aastrom Biosciences, Inc. (Nasdaq:   ASTM) announced today that Steven N. Wolff,
 M.D. has joined the Company as Vice President Medical Research.  In this newly
 created position, Dr. Wolff will be responsible for clinical and biological
 research activities at Aastrom, in addition to furthering the development of
 research collaborations in the rapidly emerging field of cell therapeutics.
     "Aastrom has progressed to the stage where a majority of our operations
 are now focused in the clinic, with both trials and commercial applications.
 The addition of Dr. Wolff to Aastrom's senior management team is welcomed, and
 is expected to greatly improve our clinical expertise and help move our
 products into medical practice," stated R. Douglas Armstrong, Ph.D., President
 and Chief Executive Officer of Aastrom.  "Dr. Wolff is a highly credentialed
 medical leader with extensive leadership experience in stem cell
 transplantation, hematology and oncology, which is ideally matched with
 Aastrom's lead stem cell and cancer vaccine product programs."
     Prior to joining Aastrom, Dr. Wolff held various distinguished positions
 at the Vanderbilt University School of Medicine, most recently as Professor of
 Medicine in the Division of Hematology/Oncology, and as Director of the Bone
 Marrow Transplant Program.  In addition, Dr. Wolff has served on the National
 Marrow Donor Program Council since 1995, as the Council's President in 1997,
 and as the Chairman of the Finance Committee.  Currently, Dr. Wolff
 participates as a Board Member for the Lance Armstrong Foundation, having
 served as its Board President in 1998.  Dr. Wolff holds an M.D. from the
 University of Illinois, with postgraduate training at Vanderbilt University
 School of Medicine and Washington University School of Medicine, and holds an
 undergraduate degree from Queens College.
     Aastrom is pioneering the development of proprietary cell therapeutics and
 cell products based on the Company's dual-technology platforms: patented
 "single-pass perfusion" providing cells with enhanced biological function, and
 patented GMP-compliant system automation facilitating the delivery of cells
 for therapeutic use into medical practice.  These technologies are integrated
 into the AastromReplicell(TM) System that is designed to uniquely standardize
 and automate the processes involved in producing high quality therapeutic
 cells.  Aastrom is developing the DC-I dendritic cell product for use in the
 rapidly emerging cancer vaccine market, and the OC-I bone progenitor cell
 product for the treatment of degenerative bone diseases such as osteoporosis.
 The AastromReplicell(TM) System, the SC-I bone marrow stem cell product and
 the CB-I cord blood stem cell product have received CE Mark approval necessary
 for European marketing and are in late-stage U.S. clinical trials.  These
 products are not available for sale at this time in the U.S., except for
 research or investigational use.
     Please visit our website at http://www.aastrom.com
 
     This document contains forward-looking statements, including without
 limitation, statements concerning intended areas of research, product and
 clinical development objectives, clinical trial results, commercialization
 plans and progress, potential product applications, and potential advantages
 of the AastromReplicell(TM) System, which involve certain risks and
 uncertainties.  The forward-looking statements are also identified through use
 of the words "designed," "expected," and other words of similar meaning.
 Actual results may differ significantly from the expectations contained in the
 forward-looking statements.  Among the factors that may result in differences
 are the results obtained from clinical trial and development activities,
 regulatory approval requirements, the availability of resources, competitive
 developments, the availability of resources and the allocation of resources
 among different potential uses.  These and other significant factors are
 discussed in greater detail in Aastrom's Annual Report on Form-10K and other
 filings with the Securities and Exchange Commission.
 
     CONTACTS:  Todd E. Simpson              Noonan/Russo Communications, Inc.
                VP Finance                   Phone:  212-696-4455
                & Administration, CFO        Hala Bashir, ext. 356 (media)
                Aastrom Biosciences, Inc.    David Walsey, ext. 230 (investors)
                Phone:  734-930-5777
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X75876227
 
 SOURCE  Aastrom Biosciences, Inc.